Postprandial plasma glucose effects of once-weekly albiglutide for the treatment of type 2 diabetes

Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial

(2015) Juris J. Meier et al.   DIABETES CARE

A randomized dose-finding study demonstrating the efficacy and tolerability of albiglutide in Japanese patients with type 2 diabetes mellitus

(2014) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Efficacy and Safety of the Once-Weekly GLP-1 Receptor Agonist Albiglutide Versus Sitagliptin in Patients With Type 2 Diabetes and Renal Impairment: A Randomized Phase III Study

(2014) Lawrence A. Leiter et al.   DIABETES CARE

Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro

(2014) Julio Rosenstock et al.   DIABETES CARE

HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin

(2014) Bo Ahrén et al.   DIABETES CARE

Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1)

(2014) Carol Wysham et al.   DIABETES CARE

Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5

(2014) P. D. Home et al.   DIABETES OBESITY & METABOLISM

Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled

(2014) J. Reusch et al.   DIABETES OBESITY & METABOLISM

Pronounced reduction of postprandial glucagon by lixisenatide: a meta-analysis of randomized clinical trials

(2014) B. Ahrén et al.   DIABETES OBESITY & METABOLISM

HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea

(2014) Peter N. Weissman et al.   DIABETOLOGIA

Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial

(2014) Kathleen M Dungan et al.   LANCET

Clinical Pharmacology of Albiglutide, a GLP-1 Receptor Agonist

(2014) Malcolm A. Young et al.   POSTGRADUATE MEDICINE

Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study

(2014) Richard E Pratley et al.   Lancet Diabetes & Endocrinology

Pharmacodynamic characteristics of lixisenatide once daily versus liraglutide once daily in patients with type 2 diabetes insufficiently controlled on metformin

(2013) C. Kapitza et al.   DIABETES OBESITY & METABOLISM

GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus

(2012) Juris J. Meier   Nature Reviews Endocrinology

Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?

(2010) M. A. Nauck et al.   DIABETOLOGIA

Albiglutide

(2010) J. Rosenstock et al.   DRUGS OF THE FUTURE

Safety, tolerability, pharmacokinetics and pharmacodynamics of albiglutide, a long-acting GLP-1-receptor agonist, in Japanese subjects with type 2 diabetes mellitus

(2009) Yutaka Seino et al.   CURRENT MEDICAL RESEARCH AND OPINION

Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6)

(2009) John B Buse et al.   LANCET

Three-Year Efficacy of Complex Insulin Regimens in Type 2 Diabetes

(2009) Rury R. Holman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: A randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study

(2008) Sherwyn L. Schwartz et al.   CLINICAL THERAPEUTICS

Pharmacodynamics, Pharmacokinetics, Safety, and Tolerability of Albiglutide, a Long-Acting Glucagon-Like Peptide-1 Mimetic, in Patients with Type 2 Diabetes

(2008) Jessica E. Matthews et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study

(2008) Daniel J Drucker et al.   LANCET